CLM Stock Overview A biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Clearside Biomedical, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Clearside Biomedical Historical stock prices Current Share Price US$1.01 52 Week High US$1.41 52 Week Low US$0.91 Beta 2.2 1 Month Change 2.02% 3 Month Change n/a 1 Year Change 12.22% 3 Year Change -74.56% 5 Year Change -52.36% Change since IPO -89.96%
Recent News & Updates
Clearside Biomedical, Inc. Announces Board Changes Nov 05
Clearside Biomedical, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 31
Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes Oct 09
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD Aug 27
Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Aug 01
Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China Jul 30 See more updates
Clearside Biomedical, Inc. Announces Board Changes Nov 05
Clearside Biomedical, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 31
Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes Oct 09
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD Aug 27
Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Aug 01
Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China Jul 30
Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board Jul 11
First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.15 loss in 1Q 2023) May 12
Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024 May 01
Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024 Apr 28
Insider recently bought €122k worth of stock Apr 22
New minor risk - Market cap size Apr 19
Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors Apr 16
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer Mar 19
Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024 Mar 01
Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million. Feb 09 Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million. Feb 08
Clearside Biomedical, Inc. has filed a Follow-on Equity Offering. Feb 07
Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD Dec 14
Third quarter 2023 earnings released: US$0.15 loss per share (vs US$0.13 loss in 3Q 2022) Nov 16
New major risk - Negative shareholders equity Nov 10
Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023 Nov 01
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting Oct 18
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting Oct 17
Clearside Biomedical Receives Non-Compliance Notice from Nasdaq Oct 01
Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 03
Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting Aug 01
Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema Jul 11
Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD Jun 02
First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.13 loss in 1Q 2022) May 13
High number of new directors Apr 01
Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023 Feb 07
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Feb 03
Clearside Biomedical, Inc. Announces Positive Results in Safety, Durability and Biologic Effect in Oasis Phase 1/2A Clinical Trial of Suprachoroidal CLS-AX (axitinib Injectable Suspension) in Wet AMD Patients Nov 10
Clearside Biomedical, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Nov 03
High number of new directors Aug 31
Clearside Biomedical, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Clearside Biomedical Completes Dosing in Oasis Phase 1/2A Clinical Trial of CLS-AX in Wet AMD Patients Jul 27
Clearside Biomedical, Inc. Appoints Susan Coultas as Chief Clinical Officer Jun 15
First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.13 loss in 1Q 2021) May 13
High number of new directors May 10 Clearside Biomedical, Inc., Annual General Meeting, Jun 22, 2022
Bausch + Lomb and Clearside Biomedical, Inc. Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis Mar 29
High number of new directors Mar 16
Clearside Biomedical, Inc. Appoints Benjamin R. Yerxa to Its Board of Directors Mar 05
Clearside Biomedical, Inc. to Report Q4, 2021 Results on Mar 10, 2022 Feb 26
Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference Feb 15
High number of new and inexperienced directors Jan 10
Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD Dec 22
High number of new and inexperienced directors Nov 17
High number of new and inexperienced directors Oct 26
High number of new and inexperienced directors Oct 06
Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients Sep 23
High number of new and inexperienced directors Sep 10
Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2020) Aug 12
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD Jun 16
Bausch Health and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE (Triamcinolone Acetonide Suprachoroidal Injectable Suspension) Jun 03
First quarter 2021 earnings released: US$0.13 loss per share (vs US$0.065 loss in 1Q 2020) May 19
Clearside Biomedical, Inc. Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis May 04
Full year 2020 earnings released: US$0.39 loss per share (vs US$0.81 loss in FY 2019) Mar 13
Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (Axitinib Injectable Suspension) for the Treatment of Wet AMD Mar 04
Clearside Biomedical, Inc. to Report Q4, 2020 Results on Mar 10, 2021 Feb 25
New 90-day high: €3.41 Feb 12
Clearside Biomedical, Inc.(NasdaqGM:CLSD) dropped from Russell 2000 Dynamic Index Jan 28
New 90-day high: €3.35 Jan 20
Clearside Biomedical, Inc. Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD Jan 13
New 90-day high: €2.47 Jan 04
Insider recently bought €82k worth of stock Dec 30
Insider recently bought €87k worth of stock Dec 05
Insider recently bought €86k worth of stock Nov 26
New 90-day high: €1.54 Nov 26
Insider recently bought €89k worth of stock Nov 19
Clearside Biomedical, Inc. Announces Data Presentations at the American Academy Ophthalmology 2020 Annual Meeting and Publication on the Suprachoroidal Injection Procedure in Translational Vision Science and Technology Nov 18
Third quarter 2020 earnings released: US$0.052 loss per share Nov 11
Revenue beats expectations Nov 11
Clearside Biomedical, Inc. to Report Q3, 2020 Results on Nov 10, 2020 Oct 31
New 90-day low: €1.15 Oct 21
New 90-day low: €1.21 Sep 29
New 90-day low - €1.29 Aug 29
First half earnings released Aug 11
New 90-day low - €1.38 Jul 30 Shareholder Returns CLM DE Pharmaceuticals DE Market 7D 0% -2.2% -2.0% 1Y 12.2% -15.6% 6.9%
See full shareholder returns
Return vs Market: CLM underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is CLM's price volatile compared to industry and market? CLM volatility CLM Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: CLM's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine CLM's volatility change over the past year.
About the Company Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Show more Clearside Biomedical, Inc. Fundamentals Summary How do Clearside Biomedical's earnings and revenue compare to its market cap? CLM fundamental statistics Market cap €63.63m Earnings (TTM ) -€30.66m Revenue (TTM ) €7.41m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CLM income statement (TTM ) Revenue US$7.70m Cost of Revenue US$0 Gross Profit US$7.70m Other Expenses US$39.58m Earnings -US$31.88m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.42 Gross Margin 100.00% Net Profit Margin -413.84% Debt/Equity Ratio -141.4%
How did CLM perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 21:03 End of Day Share Price 2024/11/25 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Clearside Biomedical, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Daniil Gataulin Chardan Capital Markets, LLC Yi Chen H.C. Wainwright & Co. Esther Lannie Hong Janney Montgomery Scott LLC
Show 10 more analysts 
